Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) is anticipated to release its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($444.2941) per share and revenue of $4.85 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) last posted its earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, topping the consensus estimate of ($782.25) by $766.55. The business had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $4.24 million.
Jaguar Animal Health Stock Performance
NASDAQ JAGX opened at $0.48 on Thursday. The company’s 50 day moving average is $5.69 and its 200-day moving average is $117.33. Jaguar Animal Health has a 12-month low of $0.45 and a 12-month high of $1,102.50. The company has a quick ratio of 0.40, a current ratio of 0.69 and a debt-to-equity ratio of 0.35. The firm has a market cap of $945,750.00, a P/E ratio of -0.00 and a beta of -0.09.
Wall Street Analyst Weigh In
Several research analysts recently commented on JAGX shares. Wall Street Zen raised shares of Jaguar Animal Health to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Stock Report on Jaguar Animal Health
Jaguar Animal Health Company Profile
Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and commercializing plant-based pharmaceuticals for gastrointestinal disorders in animals. Its research programs are designed to address conditions affecting companion animals, livestock and other animal species, with an emphasis on therapies that support intestinal function and overall animal health.
The company’s lead product is Canalevia-CA1, a prescription product containing crofelemer. Canalevia-CA1 received conditional approval from the U.S.
See Also
- Five stocks we like better than Jaguar Animal Health
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
